Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Shining new light on drug research: Global drug research programme comes to Diamond in Oxfordshire

28.05.2008
Diamond has announced that USA-based global biotechnology company Vertex Pharmaceuticals Incorporated is the first industrial user at the UK’s world class new research facility, Diamond Light Source.

Vertex will utilise the Diamond Synchrotron, the largest scientific facility to be built in the UK for 40 years, to advance its research programmes for the treatment of serious diseases. With a UK office in Milton Park in South Oxfordshire, Vertex is well-positioned to use the Chilton-based synchrotron, which was officially opened by Her Majesty the Queen in October 2007.

Diamond is able to produce intensely focused synchrotron light in the form of X-rays, infrared and ultraviolet, which will be used by Vertex and other companies to investigate the atomic details of how novel drugs bind to proteins involved in human diseases.

These types of structural studies have become a cornerstone for the understanding of biological processes and an invaluable element of modern medical research, leading to more rational design of therapeutic agents. Diamond will enable Vertex to generate this information at a significantly higher rate than currently possible.

... more about:
»LIGHT »Protein »Synchrotron »Vertex »X-ray »compound

Founded in the USA in 1989, Vertex has been involved in rational drug design from its outset; using synchrotron techniques to determine the structures of biological proteins that play a role in serious diseases in order to inform more intelligent creation of therapeutic molecules. In 1999, Vertex established a UK research and development site to utilize European sources of expertise in the field of structural biology. Vertex currently has a number of compounds in clinical development, including drug candidates for cystic fibrosis and rheumatoid arthritis, plus their lead compound, telaprevir – an oral protease inhibitor for the treatment of hepatitis V viral infection.

Vertex’s current research programme at Diamond Light Source will use X-ray crystallographic techniques to focus on the interaction of small molecule inhibitors with proteins implicated in a variety of human cancers, bacterial infection and the development of immune diseases. The exquisitely fine detail revealed by Diamond’s X-rays will allow Vertex scientists to understand how the inhibitor compounds may be improved to increase their potency and selectivity for the desired protein target. Ultimately, this will lead to the discovery of more efficacious therapeutic drugs.. The exceptional quality and intensity of light produced by the Diamond synchrotron will enable Vertex scientists to generate data and resolve new structures from ever smaller crystals and within shorter timeframes than ever before, effectively speeding up the drug discovery process and allowing even the most complex drug targets to be tackled.

Dr Graham Cheetham, a Research Fellow at Vertex, carried out preliminary trials at Diamond in December 2007 and was impressed with the facility’s resources. He says: “Vertex continuously seeks new technologies and new methods that will improve our drug discovery and development efforts, and Diamond’s synchrotron brings to Vertex a novel tool for advancing our capabilities. To conduct cutting-edge science you need cutting-edge tools, and Diamond is a centre of excellence when it comes to its equipment and scientists.”

The benefits of using Diamond are recognised companywide. Dr Julian Golec, Senior Vice President, Vertex UK, says: “We believe synchrotron research will continue to play a major role in our drug discovery and development efforts, and we look forward to our continued work with Diamond in the UK. Vertex is committed to developing drugs for serious diseases. As our targets for medical intervention become more complex, state of the art facilities and technologies like those at Diamond are central to our continued progress in the understanding of biological processes that enable innovative drug design.”

Gerd Materlik, Chief Executive at Diamond, welcomes other industrial scientists who would like to come and visit Diamond to discover how it can aid their research. He says: “Synchrotrons are well established as valuable aids to industrial research in many areas, from structural biology through to engineering. Diamond has a wide range of applications and is, therefore, an essential tool to numerous fields of scientific research. There are many companies that may be able to benefit from using the outstanding tools and expertise that we have at this cutting-edge facility. Beamtime varies in cost depending on a number of factors, such as: length of time required for experiments; complexity; and level of support required.”

Sarah Bucknall | alfa
Further information:
http://www.diamond.ac.uk

Further reports about: LIGHT Protein Synchrotron Vertex X-ray compound

More articles from Life Sciences:

nachricht 'Y' a protein unicorn might matter in glaucoma
23.10.2017 | Georgia Institute of Technology

nachricht Microfluidics probe 'cholesterol' of the oil industry
23.10.2017 | Rice University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Salmonella as a tumour medication

HZI researchers developed a bacterial strain that can be used in cancer therapy

Salmonellae are dangerous pathogens that enter the body via contaminated food and can cause severe infections. But these bacteria are also known to target...

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

3rd Symposium on Driving Simulation

23.10.2017 | Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

 
Latest News

Microfluidics probe 'cholesterol' of the oil industry

23.10.2017 | Life Sciences

Gamma rays will reach beyond the limits of light

23.10.2017 | Physics and Astronomy

The end of pneumonia? New vaccine offers hope

23.10.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>